Atlas of Non-FDG PET-CT in Diagnostic Oncology

Name: Atlas of Non-FDG PET-CT in Diagnostic Oncology
Brand: International Atomic Energy Agency
Price: 47.99 EUR
Availability: OnlineOnly

IAEA(Autor*in)

International Atomic Energy Agency (Verlag)

Erschienen am 10. November 2021

239 Seiten

E-Book

ePUB mit Adobe-DRM

Systemvoraussetzungen

978-92-0-129120-2 (ISBN)

47,99 €inkl. 7% MwSt.

Systemvoraussetzungen

für ePUB mit Adobe-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

Weitere Details

Inhalt

Intro
1. INTRODUCTION
1.1. Background
1.2. Objective
1.3. Scope
1.4. Structure
2. ACETATE (11C)
2.1. General characteristics
2.2. Pharmacokinetics
2.2.1. Physiological biodistribution and metabolism
2.2.2. Mechanism of retention
2.2.3. Pharmacology and toxicology
2.3. Methodology
2.3.1. Activity, administration, dosimetry
2.3.2. Imaging protocol
2.4. Clinical aspects
2.4.1. Indications
3. Bevacizumab (89Zr)
3.1. General characteristics
3.2. Pharmacokinetics
3.2.1. Metabolism
3.2.2. Mechanism of retention
3.2.3. Pharmacology and toxicology
3.3. Methodology
3.3.1. Activity, administration, dosimetry
3.3.2. Imaging protocol
3.4. Clinical aspects
3.4.1. Indications
4. Choline (11C)
4.1. General characteristics
4.2. Pharmacokinetics
4.2.1. Physiological biodistribution and metabolism
4.2.2. Mechanism of retention
4.2.3. Pharmacology and toxicology
4.3. Methodology
4.3.1. Activity, administration, dosimetry
4.3.2. Imaging protocol
4.4. Clinical aspects
4.4.1. Indications
5. Choline (18F)
5.1. General characteristics
5.2. Pharmacokinetics
5.2.1. Physiological biodistribution and metabolism
5.2.2. Mechanism of retention
5.2.3. Pharmacology and toxicology
5.3. Methodology
5.3.1. Activity, administration, dosimetry
5.3.2. Imaging protocol
5.4. Clinical aspects
5.4.1. Indications
6. FLUORO-DIHYDROTESTOSTERONE - FDHT (18F)
6.1. General characteristics
6.2. Pharmacokinetics
6.2.1. Physiological biodistribution and metabolism
6.2.2. Mechanism of retention
6.2.3. Pharmacology and toxicology
6.3. Methodology
6.3.1. Activity, administration, dosimetry
6.3.2. Imaging protocol
6.4. Clinical aspects
6.4.1. Indications
7. F-DOPA (18F)
7.1. General characteristics
7.2. Pharmacokinetics
7.2.1. Physiological biodistribution and metabolism
7.2.2. Mechanism of retention
7.3. Methodology
7.3.1. Activity, administration, dosimetry
7.3.2. Imaging protocol
7.4. Clinical aspects
7.4.1. Indications
8. Fluoroestradiol, FES (18F)
8.1. General characteristics
8.2. Pharmacokinetics
8.2.1. Physiological biodistribution and metabolism
8.2.2. Mechanism of retention
8.2.3. Pharmacology and toxicology
8.3. Methodology
8.3.1. Activity, administration, dosimetry
8.3.2. Imaging protocol
8.4. Clinical aspects
8.4.1. Indications
9. Fluoroethyl-tyrosine, FET (18F)
9.1. General characteristics
9.2. Pharmacokinetics
9.2.1. Physiological biodistribution and metabolism
9.2.2. Mechanism of retention
9.2.3. Pharmacology and toxicology
9.3. Methodology
9.3.1. Activity, administration, dosimetry
9.3.2. Imaging protocol
9.4. Clinical aspects
9.4.1. Indications
10. FLUOROTHYMIDINE, FLT (18F)
10.1. General characteristics
10.2. Pharmacokinetics
10.2.1. Physiological biodistribution and metabolism
10.2.2. Mechanism of retention
10.2.3. Pharmacology and toxicology
10.3. Methodology
10.3.1. Activity, administration, dosimetry
10.3.2. Imaging protocol
10.4. Clinical aspects
10.4.1. Indications
11. FLUCICLOVINE, FACBC (18F)
11.1. General characteristics
11.2. Pharmacokinetics
11.2.1. Physiological biodistribution and metabolism
11.2.2. Mechanism of retention
11.2.3. Pharmacology and toxicology
11.3. Methodology
11.3.1. Activity, administration, dosimetry
11.3.2. Imaging protocol
11.4. Clinical aspects
11.4.1. Indications
12. FMISO (18F)
12.1. General characteristics
12.2. Pharmacokinetics
12.2.1. Physiological biodistribution and metabolism
12.2.2. Mechanism of retention
12.2.3. Pharmacology and toxicology
12.3. Methodology
12.3.1. Activity, administration, dosimetry
12.3.2. Imaging protocol
12.4. Clinical aspects
12.4.1. Indications
13. FAZA (18F)
13.1. General characteristics
13.2. Pharmacokinetics
13.2.1. Mechanism of retention
13.3. Methodology
13.3.1. Activity, administration, dosimetry
13.3.2. Imaging protocol
13.4. Clinical aspects
13.4.1. Indications
14. EXENDIN (68Ga)
14.1. General characteristics
14.2. Pharmacokinetics
14.2.1. Physiological biodistribution and metabolism
14.2.2. Mechanism of retention
14.2.3. Pharmacology and toxicology
14.3. Methodology
14.3.1. Activity, administration, dosimetry
14.3.2. Imaging protocol
14.4. Clinical aspects
14.4.1. Indications
15. 5-HYDROXYTRYPTOPHAN, HTP (11C)
15.1. General characteristics
15.2. Pharmacokinetics
15.2.1. Physiological biodistribution and metabolism
15.2.2. Mechanism of retention
15.2.3. Pharmacology and toxicology
15.3. Methodology
15.3.1. Activity, administration, dosimetry
15.3.2. Imaging protocol
15.4. Clinical aspects
15.4.1. Indications
16. METHIONINE (11C)
16.1. General characteristics
16.2. Pharmacokinetics
16.2.1. Physiological biodistribution and metabolism
16.2.2. Mechanism of retention
16.2.3. Pharmacology and toxicology
16.3. Methodology
16.3.1. Activity, administration, dosimetry
16.3.2. Imaging protocol
16.4. Clinical aspects
16.4.1. Indications
17. SODIUM FLUORIDE, NaF (18F)
17.1. General characteristics
17.2. Pharmacokinetics
17.2.1. Physiological biodistribution and metabolism
17.2.2. Mechanism of retention
17.2.3. Pharmacology and toxicology
17.3. Methodology
17.3.1. Activity, administration, dosimetry
17.3.2. Imaging protocol
17.4. Clinical aspects
17.4.1. Indications
18. SODIUM IODIDE, NaI (124I)
18.1. General characteristics
18.2. Pharmacokinetics
18.2.1. Physiological biodistribution and metabolism
18.2.2. Mechanism of retention
18.2.3. Pharmacology and toxicology
18.3. Methodology
18.3.1. Activity, administration, dosimetry
18.3.2. Imaging protocol
18.4. Clinical aspects
18.4.1. Indications
19. PSMA LIGAND (68Ga)
19.1. General characteristics
19.2. Pharmacokinetics
19.2.1. Physiological biodistribution and metabolism
19.2.2. Mechanism of retention
19.2.3. Pharmacology and toxicology
19.3. Methodology
19.3.1. Activity, administration, dosimetry
19.3.2. Imaging protocol
19.4. Clinical aspects
19.4.1. Indications
20. SOMATOSTATIN ANALOGUES (68Ga)
20.1. General characteristics
20.2. Pharmacokinetics
20.2.1. Physiological biodistribution and metabolism
20.2.2. Mechanism of retention
20.2.3. Pharmacology and toxicology
20.3. Methodology
20.3.1. Activity, administration, dosimetry
20.3.2. Imaging protocol
20.4. Clinical aspects
20.4.1. Indications
21. TRASTUZUMAB (89Zr)
21.1. General characteristics
21.2. Pharmacokinetics
21.2.1. Physiological biodistribution and metabolism
21.2.2. Mechanism of retention
21.2.3. Pharmacology and toxicology
21.3. Methodology
21.3.1. Activity, administration, dosimetry
21.3.2. Imaging protocol
21.4. Clinical aspects
21.4.1. Indications
22. YTTRIUM MICROSPHERES AFTER SELECTIVE INTERNAL RADIATION THERAPY (90Y)
22.1. General characteristics
22.2. Pharmacokinetics
22.2.1. Physiological biodistribution and metabolism
22.2.2. Mechanism of retention
22.2.3. Pharmacology and toxicology
22.3. Methodology
22.3.1. Activity, administration, dosimetry
22.3.2. Imaging protocol
22.4. Clinical aspects
22.4.1. Indications
ABBREVIATIONS
REFERENCES
LIST OF CONTRIBUTORS TO DRAFTING AND REVIEW

Systemvoraussetzungen

Als PDF speichern Als Link merken